

# Mandeep Mehra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1765131/publications.pdf>

Version: 2024-02-01

573  
papers

39,701  
citations

4942

84  
h-index

3312

184  
g-index

617  
all docs

617  
docs citations

617  
times ranked

43259  
citing authors

#	ARTICLE	IF	CITATIONS
1	Concurrent valvular procedures during left ventricular assist device implantation and outcomes: A comprehensive analysis of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 trial portfolio. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 166, 1684-1694.e18.	0.4	6
2	Cardiopulmonary transit time: A novel PET imaging biomarker of in vivo physiology for risk stratification of heart transplant recipients. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1234-1244.	1.4	4
3	New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. <i>Clinical Research in Cardiology</i> , 2022, 111, 50-59.	1.5	6
4	A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: A United Kingdom perspective. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 174-186.	0.3	13
5	Cardiac Xenotransplantation: Rebirth Amidst an Uncertain Future. <i>Journal of Cardiac Failure</i> , 2022, 28, 873-874.	0.7	10
6	The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic. <i>European Heart Journal</i> , 2022, 43, 2603-2618.	1.0	27
7	Usefulness of ventilatory inefficiency in predicting prognosis across the heart failure spectrum. <i>ESC Heart Failure</i> , 2022, 9, 293-302.	1.4	10
8	Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies. <i>European Heart Journal</i> , 2022, 43, 2237-2246.	1.0	23
9	Outcomes in Smaller Body Size Adults After HeartMate 3 Left Ventricular Assist Device Implantation. <i>Annals of Thoracic Surgery</i> , 2022, 114, 2262-2269.	0.7	3
10	Center Variability in Patient Outcomes Following HeartMate 3 Implantation: An Analysis of the MOMENTUM 3 Trial. <i>Journal of Cardiac Failure</i> , 2022, 28, 1158-1168.	0.7	12
11	Medical decisions in organ donors and heart transplant candidates with history of COVID-19 infection: An international practice survey. <i>Clinical Transplantation</i> , 2022, 36, .	0.8	3
12	Inflammation and remodeling pathways and risk of cardiovascular events in patients with ischemic heart failure and reduced ejection fraction. <i>Scientific Reports</i> , 2022, 12, .	1.6	14
13	Global challenges in left ventricular assist device therapy: a tale across two continents. <i>European Journal of Heart Failure</i> , 2022, 24, 1316-1318.	2.9	3
14	Cardiac Xenotransplantation. <i>JACC Basic To Translational Science</i> , 2022, 7, 716-729.	1.9	11
15	Is There an Obesity Paradox in Cardiogenic Shock?. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	1
16	Hospitalization Patterns and Impact of a Magnetically-Levitated Left Ventricular Assist Device in the MOMENTUM 3 Trial. <i>JACC: Heart Failure</i> , 2022, 10, 470-481.	1.9	19
17	The Heart-Gut Microbiome Intersection in Heart Failure. , 2022, 2, 222-225.		0
18	Plasma <sc>D</sc>-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the <sc>COMMANDERâ€¢HF</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 648-656.	2.9	13

#	ARTICLE	IF	CITATIONS
19	Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. American Heart Journal, 2021, 232, 105-115.	1.2	15
20	Impact of Geographic Region on the COMMANDER-HF Trial. JACC: Heart Failure, 2021, 9, 201-211.	1.9	6
21	Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHEBUS, and EXAMINE. Clinical Research in Cardiology, 2021, 110, 1554-1563.	1.5	5
22	A principal components analysis of factors associated with successful implementation of an LVAD decision support tool. BMC Medical Informatics and Decision Making, 2021, 21, 106.	1.5	3
23	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. European Heart Journal, 2021, 42, 1254-1269.	1.0	78
24	Rural-Urban Differences in Mortality From Ischemic Heart Disease, Heart Failure, and Stroke in the United States. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007341.	0.9	18
25	Primary results of long-term outcomes in the <sc>MOMENTUM</sc> 3 pivotal trial and continued access protocol study phase: a study of 2200 <sc>HeartMate</sc> 3 left ventricular assist device implants. European Journal of Heart Failure, 2021, 23, 1392-1400.	2.9	96
26	Clinical outcomes and healthcare expenditures in the real world with left ventricular assist devices â€” The CLEAR-LVAD study. Journal of Heart and Lung Transplantation, 2021, 40, 323-333.	0.3	26
27	Machine learning, artificial intelligence and mechanical circulatory support: A primer for clinicians. Journal of Heart and Lung Transplantation, 2021, 40, 414-425.	0.3	6
28	Left Ventricular Assist Devices at the Crossroad of Innovation in Advanced Heart Failure. Journal of Cardiac Failure, 2021, 27, 1291-1294.	0.7	16
29	Kinetics of generic tacrolimus in heart transplantation: A cautionary note. Journal of Heart and Lung Transplantation, 2021, 40, 569-572.	0.3	4
30	Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial. European Journal of Heart Failure, 2021, 23, 1226-1237.	2.9	47
31	Early aspirin use, allograft rejection, and cardiac allograft vasculopathy in heart transplantation. Clinical Transplantation, 2021, 35, e14424.	0.8	6
32	COVID-19 vaccination immune paresis in heart and lung transplantation. Journal of Heart and Lung Transplantation, 2021, 40, 763-766.	0.3	24
33	Confluence of the Physical Brain and Perceptual Mind With Ventricular Assist Devices. JACC: Heart Failure, 2021, 9, 852-854.	1.9	0
34	Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet, The, 2021, 398, 991-1001.	6.3	218
35	Bridging the palliative care chasm in advanced heart failure. International Journal of Cardiology, 2021, 338, 147-149.	0.8	1
36	Impact of Race on Clinical Outcomes After Implantation With a Fully Magnetically Levitated Left Ventricular Assist Device: An Analysis From the MOMENTUM 3 Trial. Circulation: Heart Failure, 2021, 14, e008360.	1.6	9

#	ARTICLE	IF	CITATIONS
37	Early Immunosuppression and Rapid Recovery of Cardiogenic Shock in Multisystem Inflammatory Syndrome From Convalescent COVID-19. <i>JACC: Case Reports</i> , 2021, 3, 1403-1408.	0.3	4
38	Left Ventricular Reverse Remodeling in Heart Failure: Remission to Recovery. <i>Structural Heart</i> , 2021, 5, 466-481.	0.2	19
39	Heart transplantation candidacy. <i>Current Opinion in Organ Transplantation</i> , 2021, 26, 69-76.	0.8	6
40	Redefining Left Ventricular Assist Device Indications and Strategiesâ€”Reply. <i>JAMA Cardiology</i> , 2021, 6, 120-121.	3.0	0
41	94. Infectious Complications of Left Ventricular Assist Devices. <i>Open Forum Infectious Diseases</i> , 2021, 8, S60-S60.	0.4	0
42	Evolving trends in mechanical circulatory support: Clinical development of a fully magnetically levitated durable ventricular assist device. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 223-229.	2.3	28
43	Expanding the Scope of Multimodality Imaging in Durable Mechanical Circulatory Support. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1069-1081.	2.3	7
44	Imaging the Crevasse of Left Ventricular Assist Device Infection. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1203-1205.	2.3	0
45	Reply to Geisen et al, Acquired von Willebrand syndrome and left ventricular assist devices. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 89-90.	0.3	0
46	Ambulatory Treatment of Worsening Heart Failure With Intravenous Loop Diuretics: A Four-Year Experience. <i>Journal of Cardiac Failure</i> , 2020, 26, 798-799.	0.7	13
47	Transforming the interpretation of significance in heart failure trials. <i>European Journal of Heart Failure</i> , 2020, 22, 177-180.	2.9	2
48	An early investigation of outcomes with the new 2018 donor heart allocation system in the United States. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1-4.	0.3	223
49	Secular changes in organ donor profiles and impact on heart and lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 997-1002.	0.3	2
50	Durable mechanical circulatory support across the Asia-Pacific region. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1195-1198.	0.3	7
51	Defining chronic rejection in vascularized composite allotransplantationâ€”The American Society of Reconstructive Transplantation and International Society of Vascularized Composite Allotransplantation chronic rejection working group: 2018 American Society of Reconstructive Transplantation meeting report and white paper Research goals in defining chronic rejection in vascularized composite allotransplantation. <i>SAGE Open Medicine</i> , 2020, 8, 205031212094042.	0.7	14
52	Mechanical circulatory support devices in advanced heart failure: 2020 and beyond. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 630-639.	1.6	38
53	Implications of obesity across the heart failure continuum. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 561-569.	1.6	43
54	Pharmaco-Immunomodulatory Therapy in COVID-19. <i>Drugs</i> , 2020, 80, 1267-1292.	4.9	208

#	ARTICLE	IF	CITATIONS
55	Bariatric surgery and heart transplantation outcomes: A note of caution. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 986-987.	0.3	2
56	Citizenship Status and Cardiothoracic Organ Transplantation in the United States. <i>Circulation: Heart Failure</i> , 2020, 13, e007788.	1.6	4
57	Hemocompatibility-Related Adverse Events and Survival on Venoarterial Extracorporeal Life Support. <i>JACC: Heart Failure</i> , 2020, 8, 892-902.	1.9	44
58	Cocaine use in organ donors and long-term outcome after heart transplantation: An International Society for Heart and Lung Transplantation registry analysis. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1341-1350.	0.3	11
59	Transcatheter mitral valve intervention in advanced heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1363-1365.	0.3	2
60	Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1445-1453.	1.4	235
61	Rural-Urban Differences in Cardiovascular Mortality in the US, 1999-2017. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1852.	3.8	94
62	Special Article - Palliative care considerations for cardiovascular clinicians in COVID-19. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 696-698.	1.6	5
63	Ethical considerations regarding heart and lung transplantation and mechanical circulatory support during the COVID-19 pandemic: an ISHLT COVID-19 Task Force statement. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 619-626.	0.3	31
64	Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2524.	3.8	121
65	Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 518-525.	0.3	34
66	Impact of left ventricular assist device implantation on mitral regurgitation: An analysis from the MOMENTUM 3 trial. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 529-537.	0.3	44
67	Untimely Trial Publication. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3162-3163.	1.2	0
68	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	1.0	65
69	Heart failure in the course of a pandemic. <i>European Journal of Heart Failure</i> , 2020, 22, 1755-1758.	2.9	5
70	Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: An ISHLT expert consensus statement. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 418-432.	0.3	50
71	Myocardial edema in COVID-19 on cardiac MRI. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 730-732.	0.3	14
72	Microbiota and Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2020, 382, 2378-2379.	13.9	9

#	ARTICLE	IF	CITATIONS
73	Electron microscopy of SARS-CoV-2: a challenging task – Authors' reply. <i>Lancet, The</i> , 2020, 395, e100.	6.3	64
74	Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial. <i>JACC: Heart Failure</i> , 2020, 8, 359-368.	1.9	14
75	COVID-19 illness in native and immunosuppressed states: A clinical therapeutic staging proposal. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 405-407.	0.3	1,349
76	The impact of statin therapy on neurological events following left ventricular assist system implantation in advanced heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 582-592.	0.3	4
77	Gut dysbiosis and heart failure: navigating the universe within. <i>European Journal of Heart Failure</i> , 2020, 22, 629-637.	2.9	32
78	COVID-19: Yet another coronavirus challenge in transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 408-409.	0.3	76
79	Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2020, 6, 315-322.	1.8	43
80	Extrapulmonary manifestations of COVID-19. <i>Nature Medicine</i> , 2020, 26, 1017-1032.	15.2	2,300
81	A proposed strategy for management of immunosuppression in heart transplant patients with COVID-19. <i>Clinical Transplantation</i> , 2020, 34, e14032.	0.8	14
82	Anticoagulation management strategies in heart transplantation. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 210-218.	1.6	11
83	Reappraisal of the safety and effectiveness of Impella pumps. <i>Nature Reviews Cardiology</i> , 2020, 17, 203-204.	6.1	4
84	Association of Clinical Outcomes With Left Ventricular Assist Device Use by Bridge to Transplant or Destination Therapy Intent. <i>JAMA Cardiology</i> , 2020, 5, 411.	3.0	109
85	Correlation of laboratory haemoconcentration measures with filling pressures obtained via pulmonary arterial pressure sensors in ambulatory heart failure patients. <i>European Journal of Heart Failure</i> , 2020, 22, 1907-1911.	2.9	6
86	Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, e102.	13.9	925
87	Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 774-781.	0.3	58
88	COVID-19 Illness and Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 512-514.	1.9	127
89	Evidence-based pharmacotherapy for prevention and management of cardiac allograft vasculopathy. <i>Progress in Cardiovascular Diseases</i> , 2020, 63, 194-209.	1.6	13
90	The heart-gut microbiome axis in advanced heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 891-893.	0.3	12

#	ARTICLE	IF	CITATIONS
91	Dilemma of organ donation in transplantation and the COVID-19 pandemic. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 410-411.	0.3	19
92	Endothelial cell infection and endotheliitis in COVID-19. <i>Lancet</i> , The, 2020, 395, 1417-1418.	6.3	5,100
93	Characteristics Associated With High-Performing Pediatric Heart Transplant Centers in the United States From 2006 to 2015. <i>JAMA Network Open</i> , 2020, 3, e2023515.	2.8	5
94	Abstract 13445: Patterns and Outcomes of Thoracic Organ Transplantation Across Citizenship Status in the United States. <i>Circulation</i> , 2020, 142, .	1.6	0
95	Response by Mehra and Colombo to Letter Regarding Article, "Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study: A Randomized Controlled Trial of the Heartmate 3 Versus the Heartmate II Cardiac Pump"; <i>Circulation</i> , 2019, 140, e165-e166.	1.6	1
96	Low-intensity anti-coagulation using Vitamin K antagonists and Factor X activity: A validation analysis of the MAGENTUM-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 668-669.	0.3	1
97	Cardiac CT to Diagnose Left Ventricular Assist Device Outflow Graft Twist. <i>Radiology</i> , 2019, 292, 537-537.	3.6	2
98	Adoption of hepatitis C virus-infected donor hearts: A "middle child" no more. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 918-919.	0.3	2
99	Optimal Hemodynamics During Left Ventricular Assist Device Support Are Associated With Reduced Readmission Rates. <i>Circulation: Heart Failure</i> , 2019, 12, e005094.	1.6	71
100	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. <i>European Heart Journal</i> , 2019, 40, 3593-3602.	1.0	69
101	Diagnostic Accuracy of Advanced Imaging in Cardiac Sarcoidosis. <i>Circulation: Cardiovascular Imaging</i> , 2019, 12, e008975.	1.3	54
102	Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: A prospective multicenter clinical trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 806-816.	0.3	61
103	In reply "Mona Lisa and Postpartum Hypothyroidism. <i>Mayo Clinic Proceedings</i> , 2019, 94, 544-545.	1.4	1
104	In reply "The Mona Lisa Decrypted: Another Premise. <i>Mayo Clinic Proceedings</i> , 2019, 94, 731-732.	1.4	0
105	Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 858-869.	0.3	85
106	Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm. <i>JAMA Cardiology</i> , 2019, 4, 515.	3.0	51
107	Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). <i>American Heart Journal</i> , 2019, 214, 18-27.	1.2	41
108	Long-Term Burden of Hemocompatibility Related Adverse Events in the MOMENTUM 3 Trial: Final Analysis of the 1028 Patient Cohort. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, S67.	0.3	0



#	ARTICLE	IF	CITATIONS
109	A Trial of Complete Withdrawal of Anticoagulation Therapy in the Heartmate 3 Pump. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, S113.	0.3	1
110	Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis. <i>PLoS Medicine</i> , 2019, 16, e1002797.	3.9	36
111	A Fully Magnetically Levitated Left Ventricular Assist Device " Final Report. <i>New England Journal of Medicine</i> , 2019, 380, 1618-1627.	13.9	837
112	Quality of death after left ventricular assist device implantation: More questions than answers. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 382-384.	0.3	1
113	Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961983736.	0.7	10
114	Exercise training in patients with a left ventricular assist device (ExVAD): rationale and design of a multicentre, prospective, assessor-blinded, randomized, controlled trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1152-1159.	2.9	19
115	Nine contemporary therapeutic directions in heart failure. <i>Heart Asia</i> , 2019, 11, e011150.	1.1	2
116	Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. <i>New England Journal of Medicine</i> , 2019, 380, 1606-1617.	13.9	266
117	Organ Donation and Drug Intoxication-Related Deaths in the United States. <i>New England Journal of Medicine</i> , 2019, 380, 597-599.	13.9	12
118	...Ventricular assist devices: developments in asia and global outlook for the next 10 years. , 2019, , .		0
119	Long-Term Survival After Heart Transplantation at Centers Stratified by Short-Term Performance. <i>Circulation: Heart Failure</i> , 2019, 12, e005914.	1.6	11
120	87. Heart and Lung Transplants From HCV-Viremic Donors to Uninfected Patients: Longer-Term Follow-Up. <i>Open Forum Infectious Diseases</i> , 2019, 6, S5-S5.	0.4	0
121	Case-control study of heart rate abnormalities across the breast cancer survivorship continuum. <i>Cancer Medicine</i> , 2019, 8, 447-454.	1.3	4
122	Emerging Trends in Financing of Adult Heart Transplantation in the United States. <i>JACC: Heart Failure</i> , 2019, 7, 56-62.	1.9	12
123	Resource utilization and hospital readmission associated with gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 375-383.	1.0	2
124	HDL and Heart Failure Regulation. <i>Journal of the American College of Cardiology</i> , 2019, 73, 187-189.	1.2	2
125	Postoperative bridging anticoagulation and left ventricular assist system thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 57-66.	1.0	2
126	Comprehensive Analysis of Stroke in the Long-Term Cohort of the MOMENTUM 3 Study. <i>Circulation</i> , 2019, 139, 155-168.	1.6	113



#	ARTICLE	IF	CITATIONS
127	Evolving disruption in left ventricular assist systems: forgiving but not yet forgettable. <i>European Journal of Heart Failure</i> , 2019, 21, 98-100.	2.9	7
128	Prediction of optimal outcomes in organ transplantation. <i>Intensive Care Medicine</i> , 2019, 45, 367-370.	3.9	5
129	The Dilemma of Exertional Dyspnea and Diagnosis of Heart Failure. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 781-783.	2.3	2
130	The burden of haemocompatibility with left ventricular assist systems: a complex weave. <i>European Heart Journal</i> , 2019, 40, 673-677.	1.0	101
131	Development of an Outpatient Guideline for Optimal Anticoagulation Bridging in Patients With Durable Mechanical Circulatory Support. <i>Critical Pathways in Cardiology</i> , 2018, 17, 32-37.	0.2	2
132	Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump—the MAGENTUM 1 study. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 579-586.	0.3	128
133	Social Worker-Aided Palliative Care Intervention in High-risk Patients With Heart Failure (SWAP-HF). <i>JAMA Cardiology</i> , 2018, 3, 516.	3.0	90
134	Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2018, 137, e578-e622.	1.6	503
135	Isolated hyperammonemic encephalopathy in heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 427-429.	0.3	11
136	Ischemic stroke and subsequent thrombosis within a HeartMate 3 left ventricular assist system: A cautionary tale. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 170-172.	0.3	19
137	Blood pressure and goal titration of neurohormonal antagonists: the tortoise wins again?. <i>European Journal of Heart Failure</i> , 2018, 20, 501-503.	2.9	0
138	Diagnostic and prognostic value of myocardial blood flow quantification as non-invasive indicator of cardiac allograft vasculopathy. <i>European Heart Journal</i> , 2018, 39, 316-323.	1.0	83
139	Cardiac Implantable Electronic Devices in Patients With Left Ventricular Assist Systems. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1483-1493.	1.2	26
140	Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. <i>New England Journal of Medicine</i> , 2018, 378, 1386-1395.	13.9	601
141	Impact of age, sex, therapeutic intent, race and severity of advanced heart failure on short-term principal outcomes in the MOMENTUM 3 trial. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 7-14.	0.3	35
142	A Randomized Study Comparing Rivaroxaban with Placebo in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure: The COMMANDER HF study. <i>Journal of Cardiac Failure</i> , 2018, 24, 811.	0.7	1
143	Stroke Patterns and Implications for Ventricular Functional Remodeling in Left Ventricular Assist Systems. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, S317.	0.3	0
144	Reasons for Guideline Nonadherence at Heart Failure Discharge. <i>Journal of the American Heart Association</i> , 2018, 7, e008789.	1.6	33

#	ARTICLE	IF	CITATIONS
145	Response by Netuka et al regarding the article "Evaluation of low-intensity anti-coagulation with a fully magnetically levitated centrifugal-flow circulatory pump" the MAGENTUM 1 study. Journal of Heart and Lung Transplantation, 2018, 37, 1279-1280.	0.3	0
146	Efficacy and Safety of an Intravenous Loop Diuretic Dosing Protocol for Ambulatory Management of Worsening Heart Failure. Journal of Cardiac Failure, 2018, 24, S44-S45.	0.7	0
147	Advanced heart failure: Transatlantic perspectives on the Heart Failure Association of the European Society of Cardiology position statement. European Journal of Heart Failure, 2018, 20, 1536-1539.	2.9	8
148	Left ventricular assist device use in biventricular configurations: It takes two to tango. Journal of Heart and Lung Transplantation, 2018, 37, 1391-1393.	0.3	2
149	Increasing complexity of thoracic transplantation and the rise of multiorgan transplantation around the world: Insights from the International Society for Heart and Lung Transplantation Registry. Journal of Heart and Lung Transplantation, 2018, 37, 1145-1154.	0.3	12
150	The Mona Lisa Decrypted: Allure of an Imperfect Reality. Mayo Clinic Proceedings, 2018, 93, 1325-1327.	1.4	17
151	Magnetically Levitated Cardiac Pump at 2 Years. New England Journal of Medicine, 2018, 379, 896-897.	13.9	3
152	Four factor prothrombin complex concentrate for warfarin reversal in patients with left ventricular assist devices. Journal of Thrombosis and Thrombolysis, 2018, 46, 180-185.	1.0	16
153	Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study. Circulation, 2018, 138, 1923-1934.	1.6	59
154	The Drug-Intoxication Epidemic and Solid-Organ Transplantation. New England Journal of Medicine, 2018, 378, 1943-1945.	13.9	68
155	Burden of nursing activities during hemodynamic monitoring of heart failure patients. Heart and Lung: Journal of Acute and Critical Care, 2018, 47, 304-307.	0.8	1
156	Strategy for surgical correction and mitigation of outflow graft twist with a centrifugal-flow left ventricular assist system. Journal of Heart and Lung Transplantation, 2018, 37, 670-673.	0.3	36
157	The gut microbiome and transplantation: An amazon jungle. Journal of Heart and Lung Transplantation, 2018, 37, 1043-1044.	0.3	6
158	Advancing from a "hemodynamic model" to a "mechanistic disease-modifying model" of cardiogenic shock. Journal of Heart and Lung Transplantation, 2018, 37, 1285-1288.	0.3	27
159	Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. New England Journal of Medicine, 2018, 379, 1332-1342.	13.9	265
160	A tale of the twist in the outflow graft: An analysis from the MOMENTUM 3 trial. Journal of Heart and Lung Transplantation, 2018, 37, 1281-1284.	0.3	39
161	Late-onset right heart failure after left ventricular assist device implant: quo vadis?. Journal of Heart and Lung Transplantation, 2017, 36, 26-27.	0.3	9
162	Left Ventricular Assist Devices for Advanced Heart Failure. New England Journal of Medicine, 2017, 376, 1893-1895.	13.9	15

#	ARTICLE	IF	CITATIONS
163	Antimicrobial Surgical Prophylaxis in MCS Implant Surgery and Surgical Site Infection, IMACS January 2013 to December 2015. Journal of Heart and Lung Transplantation, 2017, 36, S40.	0.3	4
164	Left Ventricular Assist Devices for Lifelong Support. Journal of the American College of Cardiology, 2017, 69, 2845-2861.	1.2	91
165	A new twist on right heart failure with left ventricular assist systems. Journal of Heart and Lung Transplantation, 2017, 36, 701-707.	0.3	83
166	Decoupling Between Diastolic Pulmonary Artery Pressure and Pulmonary Capillary Wedge Pressure Is the Strongest Negative Prognostic Factor Post Continuous Flow Ventricular Assist Device Implantation. Journal of Heart and Lung Transplantation, 2017, 36, S328-S329.	0.3	0
167	Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months. Circulation, 2017, 135, 2003-2012.	1.6	217
168	An ACE in the hole: Unraveling gastrointestinal bleeding in left ventricular assist systems An ACE In The Hole: Unraveling Gastrointestinal Bleeding in Left Ventricular Assist Systems retain- &gt;. Journal of Heart and Lung Transplantation, 2017, 36, 373-375.	0.3	5
169	Orthopnea is Frequently Under-Reported in Routine Visits Despite its Impact on Quality of Life. Journal of Cardiac Failure, 2017, 23, S54.	0.7	0
170	Estimates of PFS, TTNT Per Treatment Line and their Relationship for Multiple Myeloma Patients. Value in Health, 2017, 20, A548.	0.1	1
171	Decoupling Between Diastolic Pulmonary Artery Pressure and Pulmonary Capillary Wedge Pressure as a Prognostic Factor After Continuous Flow Ventricular Assist Device Implantation. Circulation: Heart Failure, 2017, 10, .	1.6	57
172	Postmarketing Adverse Events Related to the CardioMEMS HF System. JAMA Cardiology, 2017, 2, 1277.	3.0	46
173	Does Angiotensin Pathway Inhibition Influence Non-Surgical Bleeding in Durable Mechanical Circulatory Support?. Journal of Heart and Lung Transplantation, 2017, 36, S252-S253.	0.3	0
174	Early aspirin use and the development of cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 2017, 36, 1344-1349.	0.3	39
175	Safety and efficacy of transplantation of nurown (autologous mesenchymal stromal cells secreting) Tj ETQq1 1 0.784314 rgBT /Overload trial. Cytotherapy, 2017, 19, S23.	0.3	3
176	ISHLT Transplant Registry: Youthful Investment The Path to Progress. Journal of Heart and Lung Transplantation, 2017, 36, 1027-1036.	0.3	9
177	The scourge and enigmatic journey of cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation, 2017, 36, 1291-1293.	0.3	18
178	Challenges, diligence, and a breakthrough in donation after circulatory death in heart transplantation. Journal of Heart and Lung Transplantation, 2017, 36, 1319-1321.	0.3	6
179	Heart transplantation at 50. Lancet, The, 2017, 390, e43-e45.	6.3	12
180	Response by Mehra et al to Letter Regarding Article, Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure. Circulation, 2017, 136, 1872-1873.	1.6	0

#	ARTICLE	IF	CITATIONS
181	Guidelines for Listing Candidates for Heart Transplant. <i>JAMA Cardiology</i> , 2017, 2, 98.	3.0	11
182	Mechanical circulatory support and heart transplantation in the Asia Pacific region. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 13-18.	0.3	19
183	A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. <i>New England Journal of Medicine</i> , 2017, 376, 440-450.	13.9	618
184	Forward "MOMENTUM" in left ventricular assist systems: advanced engineering meets biology. <i>Journal of Thoracic Disease</i> , 2017, 9, E653-E655.	0.6	1
185	A Randomized Controlled Trial of a Social Worker-Aided Palliative Care Intervention in High Risk Patients with Heart Failure (SWAP-HF). <i>Journal of Cardiac Failure</i> , 2016, 22, 940.	0.7	4
186	Clinical trial design and rationale of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) investigational device exemption clinical study protocol. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 528-536.	0.3	119
187	Durable left ventricular assist device therapy in advanced heart failure: Patient selection and clinical outcomes. <i>Indian Heart Journal</i> , 2016, 68, S45-S51.	0.2	9
188	Resource Utilization and Hospital Readmission Rates Associated with Gastrointestinal Bleeding in Patients with Continuous Flow Left Ventricular Assist Devices. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, S130.	0.3	1
189	Financial Implications of Ambulatory Diuretic Therapy Instead of Hospitalization for the Treatment of Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, S104-S105.	0.7	0
190	Implementation Science and Global Connectivity: HFSA's Path Forward. <i>Journal of Cardiac Failure</i> , 2016, 22, 937-938.	0.7	1
191	Heart, lung, and vascular registries: Evolving goals, successful approaches, and ongoing innovation. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1149-1157.	0.3	26
192	Body Composition and Advanced Heart Failure Therapy. <i>JACC: Heart Failure</i> , 2016, 4, 769-771.	1.9	11
193	Evaluation of von Willebrand factor with a fully magnetically levitated centrifugal continuous-flow left ventricular assist device in advanced heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 860-867.	0.3	121
194	Comparison of Ambulatory, High-Dose, Intravenous Diuretic Therapy to Standard Hospitalization and Diuretic Therapy for Treatment of Acute Decompensated Heart Failure. <i>American Journal of Cardiology</i> , 2016, 118, 1350-1355.	0.7	14
195	Vulnerable Brain and Ventricular Assist Devices. <i>Stroke</i> , 2016, 47, 2677-2678.	1.0	4
196	Indirect Comparison Of Daratumumab Monotherapy Versus Real-World Historical Control Data In Patients With Multiple Myeloma Who Are Heavily Pre-Treated And Highly Refractory. <i>Value in Health</i> , 2016, 19, A140.	0.1	1
197	Prothrombin Complex Concentrate for Non-Bleeding Urgent Warfarin Reversal in Ventricular Assist Device Patients Undergoing Heart Transplantation. <i>Current Emergency and Hospital Medicine Reports</i> , 2016, 4, 93-97.	0.6	3
198	Clinical myocardial recovery during long-term mechanical support in advanced heart failure: Insights into moving the field forward. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 413-420.	0.3	75

#	ARTICLE	IF	CITATIONS
199	The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1-23.	0.3	1,096
200	Antidepressant use in Patients with Major Depressive Disorder: a Comparison of Treatment Resistant and Non-Treatment Resistant Episodes in the United Kingdom Using The Cprd Database. <i>Value in Health</i> , 2015, 18, A414.	0.1	1
201	Grip Strength Assessment and Early Outcomes in Hospitalized Acute Decompensated Heart Failure: A Prospective Study. <i>Journal of Cardiac Failure</i> , 2015, 21, S117.	0.7	3
202	Heart Failure: A Global Pandemic and Not Just a Disease of the West. <i>Heart Failure Clinics</i> , 2015, 11, xiii-xiv.	1.0	7
203	Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 900-909.	0.5	100
204	Evolution in Mechanical Circulatory Support. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2590-2593.	1.2	11
205	Pump thrombosis redux. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1511-1514.	0.3	12
206	Pharmacologic Options for the Management of Systolic Heart Failure: Examining Underlying Mechanisms. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1282-1292.	0.8	10
207	Site selection for heart failure clinical trials in the USA. <i>Heart Failure Reviews</i> , 2015, 20, 375-383.	1.7	13
208	Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the <sc>COMMANDER HF</sc> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 735-742.	2.9	73
209	The Hi-Tech Age of Heart Failure Management. <i>Heart Failure Clinics</i> , 2015, 11, xi-xii.	1.0	0
210	Left ventricular dimension decrement index early after axial flow assist device implantation: A novel risk marker for late pump thrombosis. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1561-1569.	0.3	5
211	MY APPROACH to left ventricular assist device therapy. <i>Trends in Cardiovascular Medicine</i> , 2015, 25, 657-658.	2.3	0
212	The International Society for Heart and Lung Transplantation Registries in the Era of Big Data With Global Reach. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 1225-1232.	0.3	11
213	The Winning Team in Heart Failure: Dimensionality of Care Redesign. <i>Heart Failure Clinics</i> , 2015, 11, ix-x.	1.0	0
214	Get a Move on Heart Failure. <i>Heart Failure Clinics</i> , 2015, 11, xiii.	1.0	2
215	Disease-modifying therapy and hospitalization risk in heart failure patients. <i>American Journal of Managed Care</i> , 2015, 21, 39-47.	0.8	1
216	Current Status of Heart Transplantation. , 2014, , 403-423.		0

#	ARTICLE	IF	CITATIONS
217	Emergent use of mechanical circulatory support devices. <i>Current Opinion in Cardiology</i> , 2014, 29, 281-284.	0.8	14
218	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. <i>Circulation</i> , 2014, 130, 94-125.	1.6	102
219	Clinical Effectiveness of Cardiac Resynchronization and Implantable Cardioverter-Defibrillator Therapy in Men and Women With Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 146-153.	1.6	39
220	Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 372-381.	0.3	26
221	The Scientific Impact of the Annual Meeting of the International Society for Heart & Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, S9.	0.3	1
222	Continuous flow left ventricular assist device related aortic root thrombosis complicated by left main coronary artery occlusion. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 119-120.	0.3	13
223	Adults with Congenital Heart Disease: Growing Pains. <i>Heart Failure Clinics</i> , 2014, 10, xiii-xiv.	1.0	0
224	Comorbid Conditions in Heart Failure: An Unhappy Marriage. <i>Heart Failure Clinics</i> , 2014, 10, ix.	1.0	3
225	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. <i>Heart Rhythm</i> , 2014, 11, 1270-1303.	0.3	16
226	HRS/ACC/AHA Expert Consensus Statement on the Use of Implantable Cardioverter-Defibrillator Therapy in Patients Who Are Not Included or Not Well Represented in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1143-1177.	1.2	118
227	Obesity Paradox, Cachexia, Frailty, and Heart Failure. <i>Heart Failure Clinics</i> , 2014, 10, 319-326.	1.0	58
228	Scientific progress in heart and lung failure, mechanical circulatory support, and transplantation: Highlights from the <i>Journal of Heart and Lung Transplantation</i> . <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 223-228.	0.3	5
229	Long-term immunosuppression and malignancy in thoracic transplantation: Where is the balance?. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 461-467.	0.3	29
230	Organ Allocation Around the World: Insights From the ISHLT International Registry for Heart and Lung Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 975-984.	0.3	38
231	Clinical Effectiveness of CRT and ICD Therapy in Heart Failure Patients by Racial/Ethnic Classification. <i>Journal of the American College of Cardiology</i> , 2014, 64, 797-807.	1.2	32
232	Heart Failure with Preserved Ejection Fraction: Bouillabaisse. <i>Heart Failure Clinics</i> , 2014, 10, xiii-xiv.	1.0	1
233	Educational affairs at the International Society for Heart and Lung Transplantation: Perspective and governance of post-graduate learning dimensions. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1189-1192.	0.3	0
234	Pharmacotherapy for Heart Failure: The More We Get to Know, the More We Need to Know. <i>Heart Failure Clinics</i> , 2014, 10, ix-x.	1.0	1

#	ARTICLE	IF	CITATIONS
235	Right heart failure: Toward a common language. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 123-126.	0.3	76
236	The vexing problem of thrombosis in long-term mechanical circulatory support. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 1-11.	0.3	176
237	A History of Devices as an Alternative to Heart Transplantation. <i>Heart Failure Clinics</i> , 2014, 10, S1-S12.	1.0	21
238	Adults with congenital heart disease and heart transplantation: Optimizing outcomes. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 873-877.	0.3	48
239	Challenges in Long-Term Mechanical Circulatory Support and Biological Replacement of the Failing Heart. <i>Circulation Journal</i> , 2014, 78, 288-299.	0.7	9
240	The Normal and Abnormal Right Heart: Introduction to a Clinical Classification. , 2014, , 1-5.		0
241	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , 2013, 18, 107-122.	1.7	51
242	The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 1147-1162.	0.3	440
243	Fat, Cachexia, and the Right Ventricle in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1671-1673.	1.2	14
244	ISHLT International Registry for Heart and Lung Transplantationâ€”Into the Fourth Decade, From Strength to Strength. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 941-950.	0.3	32
245	Atrial Fibrillation and Heart Failure: It Takes Two to Tango. <i>Heart Failure Clinics</i> , 2013, 9, xiii-xiv.	1.0	3
246	Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: Initial clinical experience. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 381-387.	0.3	114
247	â€œFlexo-dyspneaâ€ A novel clinical observation in the heart failure syndrome. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 844-845.	0.3	19
248	A World View of Heart Failure Requiring Hospitalization. <i>Heart Failure Clinics</i> , 2013, 9, ix-x.	1.0	1
249	Anticoagulation in heart failure: current status and future direction. <i>Heart Failure Reviews</i> , 2013, 18, 797-813.	1.7	28
250	Inflammation and oxidative stress induced by cigarette smoke in Lewis rat brains. <i>Journal of Neuroimmunology</i> , 2013, 254, 69-75.	1.1	100
251	Impact of Obesity and the Obesity Paradox on Prevalence and Prognosis in Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 93-102.	1.9	463
252	Durable Mechanical Circulatory Support in Advanced Heart Failure. <i>Cardiology Clinics</i> , 2013, 31, 581-593.	0.9	4



#	ARTICLE	IF	CITATIONS
253	Porcine Brachial Artery Tortuosity for In Vivo Evaluation of Neuroendovascular Devices. <i>American Journal of Neuroradiology</i> , 2013, 34, E36-E38.	1.2	8
254	Right Heart Failure: Toward a Common Language. <i>Pulmonary Circulation</i> , 2013, 3, 963-967.	0.8	28
255	Factors Associated with Improvement in Utilization of Cardiac Resynchronization Therapy in Eligible Heart Failure Patients: Findings from IMPROVE HF. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 433-443.	0.5	7
256	Advancing Immunosuppression in Heart Transplantation: "One Step Forward, Two Steps Back. <i>American Journal of Transplantation</i> , 2013, 13, 1119-1120.	2.6	3
257	Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events. <i>Vascular Health and Risk Management</i> , 2013, 9, 245.	1.0	10
258	Incremental Reduction in Risk of Death Associated With Use of Guideline-Recommended Therapies in Patients With Heart Failure: A Nested Case-Control Analysis of IMPROVE HF. <i>Journal of the American Heart Association</i> , 2012, 1, 16-26.	1.6	64
259	Balancing the Tightrope of Cardiac Allograft Rejection. <i>Circulation</i> , 2012, 125, 2971-2974.	1.6	2
260	Antioxidant N-acetyl cysteine reverses cigarette smoke-induced myocardial infarction by inhibiting inflammation and oxidative stress in a rat model. <i>Laboratory Investigation</i> , 2012, 92, 224-235.	1.7	30
261	Temporal Evolution of Susceptibility Artifacts from Coiled Aneurysms on MR Angiography: An In Vivo Canine Study. <i>American Journal of Neuroradiology</i> , 2012, 33, 655-660.	1.2	12
262	Should Left Ventricular Assist Device Should Be Standard of Care for Patients With Refractory Heart Failure Who Are Not Transplantation Candidates?. <i>Circulation</i> , 2012, 126, 3081-3087.	1.6	7
263	Race and Improvements in the Use of Guideline-Recommended Therapies for Patients With Heart Failure: Findings From IMPROVE HF. <i>Journal of the National Medical Association</i> , 2012, 104, 287-298.	0.6	8
264	B-type natriuretic peptide assessment in ambulatory heart failure patients. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 360-367.	0.6	3
265	Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: Findings from IMPROVE HF. <i>American Heart Journal</i> , 2012, 163, 49-56.e2.	1.2	127
266	The dawn of the ISHLT Mechanical Assisted Circulatory Support (IMACS) Registry: Fulfilling our mission. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 115-116.	0.3	19
267	The Heart Failure Society of America in 2020: A Vision for the Future. <i>Journal of Cardiac Failure</i> , 2012, 18, 90-93.	0.7	3
268	Emergency Cardiovascular Care: From ED to CCU and Beyond. <i>Cardiology Clinics</i> , 2012, 30, xiii-xiv.	0.9	0
269	Exercise Training as Treatment of Depression in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 291.	1.2	3
270	Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2012, 59, 232-234.	1.2	9

#	ARTICLE	IF	CITATIONS
271	Heart Transplantation Research in the Next Decade—A Goal to Achieving Evidence-Based Outcomes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1263-1269.	1.2	35
272	JHLT highlights 2011: Cardiothoracic transplantation, pulmonary hypertension, and mechanical circulatory support. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 1257-1261.	0.3	0
273	PIN8 Assessment of Tuberculosis Burden in China Using a Dynamic Disease Simulation Model. <i>Value in Health</i> , 2012, 15, A667.	0.1	0
274	Lack of Association Between Electronic Health Record Systems and Improvement in Use of Evidence-Based Heart Failure Therapies in Outpatient Cardiology Practices. <i>Clinical Cardiology</i> , 2012, 35, 187-196.	0.7	21
275	Factors Associated with Improvement in Guideline-Based Use of ICDs in Eligible Heart Failure Patients. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2012, 35, 135-145.	0.5	12
276	Medication Dosing in Outpatients With Heart Failure After Implementation of a Practice-Based Performance Improvement Intervention: Findings From IMPROVE HF. <i>Congestive Heart Failure</i> , 2012, 18, 9-17.	2.0	69
277	Rationale, design, and results from RENO-DEFEND 1: A randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure. <i>American Heart Journal</i> , 2011, 161, 1012-1023.e3.	1.2	15
278	Pharmacokinetics and pharmacodynamics of rivaroxaban and its effect on biomarkers of hypercoagulability in patients with chronic heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 218-226.	0.3	30
279	Endothelitis in cardiac allograft biopsy specimens: Possible relationship to antibody-mediated rejection. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 435-444.	0.3	22
280	682 Antibody Mediated Rejection in Heart Transplant Biopsies. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, S227.	0.3	0
281	Current and future challenges in therapy for antibody-mediated rejection. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 612-617.	0.3	58
282	The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: Evolution and current status (2005–2011). <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 601-611.	0.3	193
283	Evaluación del riesgo en pacientes en estado crítico a la espera de trasplante: un paso adelante. <i>Revista Espanola De Cardiologia</i> , 2011, 64, 175-176.	0.6	4
284	Risk Assessment in Critically Ill Patients Awaiting Transplantation: a Step Forward. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2011, 64, 175-176.	0.4	2
285	Pharmacogenetics and Clopidogrel Response in Patients Undergoing Percutaneous Coronary Interventions. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 455-459.	2.3	27
286	Impact of Exercise Training and Depression on Survival in Heart Failure Due to Coronary Heart Disease. <i>American Journal of Cardiology</i> , 2011, 107, 64-68.	0.7	100
287	Patient and Practice Factors Associated With Improvement in Use of Guideline-Recommended Therapies for Outpatients With Heart Failure (from the IMPROVE HF Trial). <i>American Journal of Cardiology</i> , 2011, 107, 250-258.	0.7	6
288	Comparison of Characteristics and Outcomes of Asymptomatic Versus Symptomatic Left Ventricular Dysfunction in Subjects 65 Years Old or Older (from the Cardiovascular Health Study). <i>American Journal of Cardiology</i> , 2011, 107, 1667-1674.	0.7	21

#	ARTICLE	IF	CITATIONS
289	Associations Between Outpatient Heart Failure Process-of-Care Measures and Mortality. <i>Circulation</i> , 2011, 123, 1601-1610.	1.6	83
290	Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. <i>Heart</i> , 2011, 97, 1607-1618.	1.2	22
291	Management of End-Stage Heart Failure. , 2011, , 876-885.		0
292	Comparison of health care resource use before and after docetaxel treatment among prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2011, 29, 215-215.	0.8	0
293	Comparison of medical resource use and associated cost before and after docetaxel treatment among prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2011, 29, e15068-e15068.	0.8	0
294	Docetaxel use, analgesics use, and survival in prostate cancer: Survival analysis using a large claims database (2003-2009).. <i>Journal of Clinical Oncology</i> , 2011, 29, e15073-e15073.	0.8	0
295	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. <i>Circulation: Heart Failure</i> , 2010, 3, 314-325.	1.6	134
296	Clinicians and Nutraceutical Use in Cardiology Patients: Ignorance and Neglect. <i>Annals of Internal Medicine</i> , 2010, 153, 65.	2.0	0
297	Adherence to Guideline-Recommended Adjunctive Heart Failure Therapies Among Outpatient Cardiology Practices (Findings from IMPROVE HF). <i>American Journal of Cardiology</i> , 2010, 105, 255-260.	0.7	38
298	Influence of Renal Function on the Use of Guideline-Recommended Therapies for Patients With Heart Failure. <i>American Journal of Cardiology</i> , 2010, 105, 1140-1146.	0.7	45
299	Outpatient Cardiology Practices With Advanced Practice Nurses and Physician Assistants Provide Similar Delivery of Recommended Therapies (Findings from IMPROVE HF). <i>American Journal of Cardiology</i> , 2010, 105, 1773-1779.	0.7	23
300	Evaluation of a capillary blood collection system for screening for hemoglobinopathies in remote areas. <i>International Journal of Laboratory Hematology</i> , 2010, 32, e57-e63.	0.7	2
301	Comparison of Medical Therapy Dosing in Outpatients Cared for in Cardiology Practices With Heart Failure and Reduced Ejection Fraction With and Without Device Therapy. <i>Circulation: Heart Failure</i> , 2010, 3, 596-605.	1.6	75
302	Gene-Based Bio-Signature Patterns and Cardiac Allograft Rejection. <i>Heart Failure Clinics</i> , 2010, 6, 87-92.	1.0	12
303	Progressive improvement in cardiac performance with continuous aortic flow augmentation (aortic) Tj ETQq1 1 0.784314 rgBT /Overl the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). <i>Journal of Heart and Lung Transplantation</i> . 2010, 29, 86-92.	0.3	3
304	Exercise-uncovered pulmonary arterial hypertension and pharmacologic therapy: Clinical benefits. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 228-229.	0.3	6
305	Gene expression profiling and cardiac allograft rejection monitoring: Is IMAGE just a mirage?. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 599-602.	0.3	33
306	International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathyâ€”2010. <i>Journal of Heart and Lung Transplantation</i> , 2010, 29, 717-727.	0.3	719

#	ARTICLE	IF	CITATIONS
307	Validation and Potential Mechanisms of Red Cell Distribution Width as a Prognostic Marker in Heart Failure. <i>Journal of Cardiac Failure</i> , 2010, 16, 230-238.	0.7	344
308	Quilty Biopsies Are Independently Associated with Improved Post Transplant Survival. <i>Journal of Cardiac Failure</i> , 2010, 16, S50.	0.7	0
309	Documentation of QRS Duration and NYHA Class in HF Patients after a Performance Improvement Initiative: IMPROVE HF. <i>Journal of Cardiac Failure</i> , 2010, 16, S70.	0.7	2
310	Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: Findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). <i>American Heart Journal</i> , 2010, 159, 238-244.	1.2	24
311	Electronic health records and quality of care for heart failure. <i>American Heart Journal</i> , 2010, 159, 635-642.e1.	1.2	26
312	Prospective evaluation of the association between cardiac troponin T and markers of disturbed erythropoiesis in patients with heart failure. <i>American Heart Journal</i> , 2010, 160, 1142-1148.	1.2	16
313	Chronic Heart Failure: Contemporary Diagnosis and Management. <i>Mayo Clinic Proceedings</i> , 2010, 85, 180-195.	1.4	177
314	PIN1 HEPATITIC-C BURDEN ASSESSMENT IN FRANCE FROM A TRANSMISSION MODEL. <i>Value in Health</i> , 2010, 13, A187.	0.1	0
315	Equitable Improvement for Women and Men in the Use of Guideline-Recommended Therapies for Heart Failure: Findings From IMPROVE HF. <i>Journal of Cardiac Failure</i> , 2010, 16, 940-949.	0.7	29
316	Does Thermal Therapy Benefit Patients With Chronic Heart Failure?â€“Replyâ€“l. <i>Mayo Clinic Proceedings</i> , 2010, 85, 693.	1.4	6
317	Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices. <i>Circulation</i> , 2010, 122, 585-596.	1.6	372
318	New Data on the Clinical Impact of Exercise Training, Fish Oils, and Statins in Heart Failure. <i>Physician and Sportsmedicine</i> , 2009, 37, 22-28.	1.0	6
319	Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009, 6, 147-157.	3.3	23
320	Tobacco Smoke Exposure in Either the Donor or Recipient Before Transplantation Accelerates Cardiac Allograft Rejection, Vascular Inflammation, and Graft Loss. <i>Circulation</i> , 2009, 120, 1814-1821.	1.6	36
321	Lack of Diagnostic and Prognostic Utility of Circulating Plasma Myeloperoxidase Concentrations in Patients Presenting with Dyspnea. <i>Clinical Chemistry</i> , 2009, 55, 59-67.	1.5	27
322	Statins and Advanced Heart Failureâ€“Alive But Barely Breathing After CORONA and GISSIâ€“HF. <i>Congestive Heart Failure</i> , 2009, 15, 157-158.	2.0	5
323	Mechanical circulatory support devices for acute heart failure syndromes: considerations for clinical trial design. <i>Heart Failure Reviews</i> , 2009, 14, 101-112.	1.7	6
324	Influence of Atrial Fibrillation on the Use of CRT and ICD Therapy in Heart Failure: Findings from IMPROVE HF. <i>Journal of Cardiac Failure</i> , 2009, 15, S64.	0.7	0

#	ARTICLE	IF	CITATIONS
325	BNP Levels in Outpatients with Heart Failure: Frequency of Assessment, Relationship to Symptoms, Disease Severity, and HF Quality of Care Measures. <i>Journal of Cardiac Failure</i> , 2009, 15, S64.	0.7	0
326	Prevalence and Characteristics of Prolonged QRS Duration in Outpatients with Left Ventricular Systolic Dysfunction: An IMPROVE HF Analysis. <i>Journal of Cardiac Failure</i> , 2009, 15, S64-S65.	0.7	0
327	Report From a Consensus Conference on the Sensitized Patient Awaiting Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 213-225.	0.3	158
328	Adverse Effects of Nicotine and Immunosuppression on Proximal Tubular Epithelial Cell Viability, Tissue Repair and Oxidative Stress Gene Expression. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 612-620.	0.3	10
329	High-density Lipoprotein Cholesterol Levels and Prognosis in Advanced Heart Failure. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 876-880.	0.3	41
330	Generic Drug Immunosuppression in Thoracic Transplantation: An ISHLT Educational Advisory. <i>Journal of Heart and Lung Transplantation</i> , 2009, 28, 655-660.	0.3	44
331	Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: Findings from IMPROVE HF. <i>American Heart Journal</i> , 2009, 157, 754-762.e2.	1.2	93
332	Prospective assessment of the occurrence of anemia in patients with heart failure: Results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. <i>American Heart Journal</i> , 2009, 157, 926-932.	1.2	45
333	Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. <i>American Heart Journal</i> , 2009, 157, 957-970.	1.2	48
334	Cardiac resynchronization therapy utilization for heart failure: Findings from IMPROVE HF. <i>American Heart Journal</i> , 2009, 158, 956-964.	1.2	48
335	Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. <i>American Heart Journal</i> , 2009, 158, 965-971.	1.2	46
336	Acute Heart Failure Syndromes in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, 254-263.	1.2	124
337	Highlights of the 2008 Scientific Sessions of the Heart Failure Society of America. <i>Journal of the American College of Cardiology</i> , 2009, 53, 514-522.	1.2	2
338	Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Diseases. <i>Journal of the American College of Cardiology</i> , 2009, 54, 585-594.	1.2	518
339	PIN4 US HEPATITIS-C BURDEN ASSESSMENT FROM A TRANSMISSION MODEL. <i>Value in Health</i> , 2009, 12, A110.	0.1	0
340	PIN54 INCREASING CHC TREATMENT RATE IN US IS A COST-SAVING STRATEGY. <i>Value in Health</i> , 2009, 12, A119.	0.1	0
341	Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and postmyocardial infarction left ventricular dysfunction: Findings from IMPROVE HF. <i>Heart Rhythm</i> , 2009, 6, 1727-1734.	0.3	50
342	Cardiomyopathy and the dilemma of geometric mitral regurgitation. <i>Current Opinion in Cardiology</i> , 2009, 24, 179-183.	0.8	4

#	ARTICLE	IF	CITATIONS
343	The progressive cardiorenal syndrome in heart failure: Mechanisms and therapeutic insights. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2008, 10, 342-348.	0.4	8
344	Test-Retest Reliability of Assessment for Intraventricular Dyssynchrony by Tissue Doppler Imaging Echocardiography—Conflicts of interest: Dr. Shorofsky is a consultant for Medtronic and Boston Scientific. Dr. Mehra is a consultant for Medtronic, Boston Scientific, and St. Jude Medical.. <i>American Journal of Cardiology</i> , 2008, 101, 645-650.	0.7	19
345	Evidence for Early Right Ventricular and Septal Mechanical Activation (Interventricular) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	0.7	10
346	The Cardiac Allograft Is Going Up in Smoke: A Call to Action. <i>American Journal of Transplantation</i> , 2008, 8, 737-738.	2.6	4
347	Clinical Implications and Longitudinal Alteration of Peripheral Blood Transcriptional Signals Indicative of Future Cardiac Allograft Rejection. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 297-301.	0.3	38
348	Simultaneous hybrid percutaneous coronary intervention and minimally invasive surgical bypass grafting: Feasibility, safety, and clinical outcomes. <i>American Heart Journal</i> , 2008, 155, 661-667.	1.2	111
349	Surgery for Severe Mitral Regurgitation and Left Ventricular Failure: What Do We Really Know?. <i>Journal of Cardiac Failure</i> , 2008, 14, 145-150.	0.7	16
350	The Diagnostic and Prognostic Utility of Circulating Serum Myeloperoxidase Levels in Patients Presenting with Dyspnea. <i>Journal of Cardiac Failure</i> , 2008, 14, S35.	0.7	0
351	Significant Gaps in Adherence to Guideline Recommended Adjunctive Heart Failure Therapies among Outpatient Cardiology Practices: Findings from IMPROVE HF. <i>Journal of Cardiac Failure</i> , 2008, 14, S87.	0.7	0
352	Comparison of Medical Treatment in Outpatients Receiving Device Therapy for Systolic Dysfunction: A Report from IMPROVE HF. <i>Journal of Cardiac Failure</i> , 2008, 14, S94.	0.7	0
353	Influence of Advance Practice Nurse and Dedicated Heart Failure Clinics on Delivery of Recommended Therapies in Outpatient Cardiology Practices: IMPROVE HF Findings. <i>Journal of Cardiac Failure</i> , 2008, 14, S101.	0.7	0
354	Baseline Predictors of Clinical Success During Randomized Assessment of Aortic Flow Therapy in Heart Failure Exacerbation Refractory to Pharmacological Therapy: Analysis of the Multi-center MOMENTUM Trial. <i>Journal of Cardiac Failure</i> , 2008, 14, 796.	0.7	1
355	Results of A Multicenter, Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular End Systolic Volume Index in Subjects with Stable Chronic Heart Failure (The COMPARE Trial) (10/7/08). <i>Journal of Cardiac Failure</i> , 2008, 14, 796-797.	0.7	2
356	PSS47 AN OBSERVATIONAL DATABASE ANALYSIS OF TREATMENT PATTERNS OF PATIENTS WITH PSORIASIS. <i>Value in Health</i> , 2008, 11, A299.	0.1	0
357	Immune Reconstitution Inflammatory Syndrome and Human Immunodeficiency Virus-Associated Myocarditis. <i>Mayo Clinic Proceedings</i> , 2008, 83, 1275-1279.	1.4	21
358	Heart Failure Care in the Outpatient Cardiology Practice Setting. <i>Circulation: Heart Failure</i> , 2008, 1, 98-106.	1.6	168
359	Effects of Continuous Aortic Flow Augmentation in Patients With Exacerbation of Heart Failure Inadequately Responsive to Medical Therapy. <i>Circulation</i> , 2008, 118, 1241-1249.	1.6	32
360	Device Therapy for Heart Failure Patients. , 2008, , 75-86.		0



#	ARTICLE	IF	CITATIONS
361	Death messengers. <i>BMJ: British Medical Journal</i> , 2007, 335, 1296-1297.	2.4	0
362	Improving the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting: The IMPROVE HF performance improvement registry. <i>American Heart Journal</i> , 2007, 154, 12-38.	1.2	103
363	Rationale, design, and methods for the Transplant-Eligible Management of Congestive Heart Failure (TMAC) trial: A multicenter clinical outcomes trial using nesiritide for TMAC. <i>American Heart Journal</i> , 2007, 153, 932-940.	1.2	3
364	The Characteristics and Prognostic Importance of NT-ProBNP Concentrations in Critically Ill Patients. <i>American Journal of Medicine</i> , 2007, 120, 1071-1077.	0.6	38
365	171: Does induction therapy influence the utility of gene expression testing for cardiac allograft rejection?. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, S121.	0.3	0
366	398: Premature termination of a prospective, open label, randomized, multicenter study of sirolimus to replace calcineurin inhibitors (CNI) in a standard care regimen of CNI, MMF and corticosteroids early after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, S203.	0.3	25
367	Induction Therapy In Heart Transplantation: Is There A Role?. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 205-209.	0.3	43
368	Transcriptional Signals of T-cell and Corticosteroid-sensitive Genes Are Associated With Future Acute Cellular Rejection in Cardiac Allografts. <i>Journal of Heart and Lung Transplantation</i> , 2007, 26, 1255-1263.	0.3	28
369	PHM5 RESTROSPECTIVE STUDY OF OUTCOMES AND COSTS IN SICKLE CELL DISEASE (SCD) PATIENTS IN US. <i>Value in Health</i> , 2007, 10, A154.	0.1	0
370	Genomic Biomarkers and Heart Transplantation. <i>Heart Failure Clinics</i> , 2007, 3, 83-86.	1.0	2
371	Sexual Activity and Chronic Heart Failure. <i>Mayo Clinic Proceedings</i> , 2007, 82, 1203-1210.	1.4	36
372	PMH52 USAGE AND PERSISTENCY OF ATYPICAL ANTI-PSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA. <i>Value in Health</i> , 2007, 10, A304.	0.1	0
373	Peak Oxygen Consumption and Heart Failure Prognosis in Women. <i>Journal of the American College of Cardiology</i> , 2007, 49, 375.	1.2	8
374	Heart Failure Quality of Care in the Outpatient Cardiology Practice Setting: A Report from IMPROVE HF. <i>Journal of Cardiac Failure</i> , 2007, 13, S172.	0.7	1
375	Disparate Effects of Left Ventricular Geometry and Obesity on Mortality in Patients With Preserved Left Ventricular Ejection Fraction. <i>American Journal of Cardiology</i> , 2007, 100, 1460-1464.	0.7	123
376	Is Heart Failure More Prevalent in Patients With Peripheral Arterial Disease? A Meta-Analysis. <i>Congestive Heart Failure</i> , 2007, 13, 319-322.	2.0	45
377	Heart Retransplantation. <i>American Journal of Transplantation</i> , 2007, 7, 2075-2081.	2.6	77
378	Imaging Markers of Adverse Remodeling: from Organ to Organelle. <i>Heart Failure Clinics</i> , 2006, 2, 117-127.	1.0	2



#	ARTICLE	IF	CITATIONS
379	Understanding the Basics of Cardiopulmonary Exercise Testing. Mayo Clinic Proceedings, 2006, 81, 1603-1611.	1.4	140
380	Utility of Impedance Cardiography for the Identification of Short-Term Risk of Clinical Decompensation in Stable Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2006, 47, 2245-2252.	1.2	175
381	HFSA 2006 Comprehensive Heart Failure Practice Guideline: Introduction and Table of Contents. Journal of Cardiac Failure, 2006, 12, e1-e2.	0.7	288
382	Executive Summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. Journal of Cardiac Failure, 2006, 12, 10-38.	0.7	491
383	Ancient Egyptian Medicine and the Concept of Heart Failure. Journal of Cardiac Failure, 2006, 12, 416-421.	0.7	36
384	The Characteristics and Prognostic Importance of NT-ProBNP Concentrations in Critically Ill Patients. Journal of Cardiac Failure, 2006, 12, S38.	0.7	0
385	Optimizing outcomes in the patient with acute decompensated heart failure. American Heart Journal, 2006, 151, 571-579.	1.2	30
386	Fish Oils Produce Anti-inflammatory Effects and Improve Body Weight in Severe Heart Failure. Journal of Heart and Lung Transplantation, 2006, 25, 834-838.	0.3	106
387	Multicenter Retrospective Analysis of Cardiovascular Risk Factors Affecting Long-term Outcome of De Novo Cardiac Transplant Recipients. Journal of Heart and Lung Transplantation, 2006, 25, 1063-1069.	0.3	84
388	Rationale and Process: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidatesâ€”2006. Journal of Heart and Lung Transplantation, 2006, 25, 1001-1002.	0.3	18
389	Listing Criteria for Heart Transplantation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidatesâ€”2006. Journal of Heart and Lung Transplantation, 2006, 25, 1024-1042.	0.3	850
390	Molecular Testing in the Management of Cardiac Transplant Recipients: Initial Clinical Experience. Journal of Heart and Lung Transplantation, 2006, 25, 1389-1395.	0.3	114
391	The promise of protein-based and gene-based clinical markers in heart transplantation: from bench to bedside. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 136-143.	3.3	12
392	Noninvasive Discrimination of Rejection in Cardiac Allograft Recipients Using Gene Expression Profiling. American Journal of Transplantation, 2006, 6, 150-160.	2.6	482
393	Mycophenolate Mofetil Reduces Intimal Thickness by Intravascular Ultrasound After Heart Transplant: Reanalysis of the Multicenter Trial. American Journal of Transplantation, 2006, 6, 993-997.	2.6	80
394	Methodological Challenges of Genomic Research-The Cargo Study. American Journal of Transplantation, 2006, 6, 1086-1087.	2.6	16
395	Contemporary Concepts in Prevention and Treatment of Cardiac Allograft Vasculopathy. American Journal of Transplantation, 2006, 6, 1248-1256.	2.6	123
396	Immunosuppression in Cardiac Transplantation: Science, Common Sense and the Heart of the Matter. American Journal of Transplantation, 2006, 6, 1243-1245.	2.6	10

#	ARTICLE	IF	CITATIONS
397	Left Ventricular Geometry and Survival in Patients With Normal Left Ventricular Ejection Fraction. American Journal of Cardiology, 2006, 97, 959-963.	0.7	156
398	Comparison of Cardiac and Peripheral Arterial Stiffening and Ventriculovascular Uncoupling in Patients With Uncomplicated Hypertension Versus Patients With Hypertension After Heart Transplantation. American Journal of Cardiology, 2006, 98, 789-792.	0.7	10
399	COMPARE: Comparison of the Effects of Carvedilol CR and Carvedilol IR on Left Ventricular Ejection Fraction in Patients with Heart Failure. American Journal of Cardiology, 2006, 98, 53-59.	0.7	11
400	Targeted in vitro and in vivo gene transfer into T Lymphocytes: potential of direct inhibition of allo-immune activation. BMC Immunology, 2006, 7, 26.	0.9	1
401	TIME ACCURATE FAST THREE-STEP WAVELET-GALERKIN METHOD FOR PARTIAL DIFFERENTIAL EQUATIONS. International Journal of Wavelets, Multiresolution and Information Processing, 2006, 04, 65-79.	0.9	14
402	Amyloidosis and the Heart. Archives of Internal Medicine, 2006, 166, 1805.	4.3	202
403	Gene Expression Profiles and B-Type Natriuretic Peptide Elevation in Heart Transplantation: More Than a Hemodynamic Marker. Circulation, 2006, 114, I-21-I-26.	1.6	53
404	All Patients With Heart Failure and Intraventricular Conduction Defect or Dyssynchrony Should Not Receive Cardiac Resynchronization Therapy. Circulation, 2006, 114, 2685-2691.	1.6	13
405	The Interaction of Vascular Stiffness and Cardiovascular Events in Women. Chest, 2005, 127, 1477-1480.	0.4	6
406	Early recognition and treatment of hypertensive heart disease. Current Opinion in Cardiology, 2005, 20, 282-289.	0.8	17
407	B-Type Natriuretic Peptide in Heart Failure. Critical Pathways in Cardiology, 2005, 4, 10-20.	0.2	16
408	Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry. American Journal of Cardiology, 2005, 95, 367-372.	0.7	43
409	Understanding B-type natriuretic peptide and its role in diagnosing and monitoring congestive heart failure. Clinical Cornerstone, 2005, 7, S7-S17.	1.0	12
410	Brain Injury and Ventricular Dysfunction: Insights Into Reversible Heart Failure. Congestive Heart Failure, 2005, 11, 99-101.	2.0	13
411	Recrudescence of Tobacco Exposure Following Heart Transplantation: Clinical Profiles and Relationship with Athero-Thrombosis Risk Markers. American Journal of Transplantation, 2005, 5, 1137-1140.	2.6	36
412	The Economic Implications of Noninvasive Molecular Testing for Cardiac Allograft Rejection. American Journal of Transplantation, 2005, 5, 1553-1558.	2.6	56
413	Time-accurate solution of advection-diffusion problems by wavelet-Taylor-Galerkin method. Communications in Numerical Methods in Engineering, 2005, 21, 313-326.	1.3	26
414	Wavelet-Taylor Galerkin Method for the Burgers Equation. BIT Numerical Mathematics, 2005, 45, 543-560.	1.0	27

#	ARTICLE	IF	CITATIONS
415	Heart Failure Devices. <i>Circulation</i> , 2005, 111, 3327-3335.	1.6	41
416	Anatomy of a patient safety event: a pediatric patient safety taxonomy. <i>Quality and Safety in Health Care</i> , 2005, 14, 422-427.	2.5	40
417	Patient Selection for Cardiac Resynchronization Therapy. <i>Circulation</i> , 2005, 111, 2146-2150.	1.6	204
418	Acetyl-L-Carnitine Improves Pain, Nerve Regeneration, and Vibratory Perception in Patients With Chronic Diabetic Neuropathy: An analysis of two randomized placebo-controlled trials. <i>Diabetes Care</i> , 2005, 28, 89-94.	4.3	210
419	Obesity and heart failure prognosis: paradox or reverse epidemiology?. <i>European Heart Journal</i> , 2005, 26, 5-7.	1.0	122
420	It Is Time To Stop Ignoring Malignancy In Heart Transplantation: A Call To Arms. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1111-1113.	0.3	32
421	Relationship Among Epicardial Coronary Disease, Tissue Myocardial Perfusion, and Survival in Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1019-1025.	0.3	26
422	A Multicenter, Prospective, Randomized, Double-Blind Trial of Basiliximab in Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1297-1304.	0.3	99
423	Three-Year Results of a Randomized, Double-Blind, Controlled Trial of Mycophenolate Mofetil Versus Azathioprine in Cardiac Transplant Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 517-525.	0.3	237
424	Nodular Endocardial Infiltrates (Quilty Lesions) Cause Significant Variability in Diagnosis of ISHLT Grade 2 and 3A Rejection in Cardiac Allograft Recipients. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, S219-S226.	0.3	140
425	The Emergence of Genomic and Proteomic Biomarkers in Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, S213-S218.	0.3	24
426	Incidental renal artery stenosis in heart transplantation: Prevalence and clinical implications. <i>American Journal of Hypertension</i> , 2005, 18, A135-A135.	1.0	0
427	A comparison of dobutamine stress echocardiography and adenosine Tc-99m Sestamibi in pre-operative cardiac evaluation for abdominal transplant candidates. <i>American Journal of Hypertension</i> , 2005, 18, A175-A175.	1.0	0
428	Bloodletting as a Cure For Dropsy: Heart Failure Down the Ages. <i>Journal of Cardiac Failure</i> , 2005, 11, 247-252.	0.7	20
429	Obesity and B-type natriuretic peptide levels in heart failure: Reply. <i>Journal of the American College of Cardiology</i> , 2005, 45, 967.	1.2	0
430	Multicenter Intravascular Ultrasound Validation Study Among Heart Transplant Recipients. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1532-1537.	1.2	372
431	Devices in heart failure: new approaches. , 2005, , 219-236.		0
432	Cardiopulmonary Exercise Testing. <i>Circulation</i> , 2004, 110, e27-31.	1.6	62

#	ARTICLE	IF	CITATIONS
433	Surrogate Markers for Late Cardiac Allograft Survival. American Journal of Transplantation, 2004, 4, 1184-1191.	2.6	25
434	BNP Consensus Panel 2004: A Clinical Approach for the Diagnostic, Prognostic, Screening, Treatment Monitoring, and Therapeutic Roles of Natriuretic Peptides in Cardiovascular Diseases. Congestive Heart Failure, 2004, 10, 1-30.	2.0	285
435	Peak exercise oxygen pulse and prognosis in chronic heart failure. American Journal of Cardiology, 2004, 93, 588-593.	0.7	92
436	Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. American Journal of Cardiology, 2004, 94, 454-458.	0.7	85
437	Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. American Journal of Cardiology, 2004, 94, 1475-1477.	0.7	125
438	Mitral regurgitation in chronic heart failure: More questions than answers?. Current Cardiology Reports, 2004, 6, 96-99.	1.3	7
439	Ventricular assist devices: Destination therapy or just another stop on the road?. Current Heart Failure Reports, 2004, 1, 36-40.	1.3	2
440	The impact of mode of donor brain death on cardiac allograft vasculopathy. Journal of the American College of Cardiology, 2004, 43, 806-810.	1.2	72
441	Reduction in C-reactive protein through cardiac rehabilitation and exercise training. Journal of the American College of Cardiology, 2004, 43, 1056-1061.	1.2	273
442	Cardiac resynchronization therapy: caveat medicus!. Journal of the American College of Cardiology, 2004, 43, 1145-1148.	1.2	73
443	Obesity and suppressed B-type natriuretic peptide levels in heart failure. Journal of the American College of Cardiology, 2004, 43, 1590-1595.	1.2	445
444	Clinico-pathological mismatch of etiological classification in heart failure: preponderance and clinical implications. Journal of Cardiac Failure, 2004, 10, S40.	0.7	0
445	The importance of geometric configuration in predicting ventricular arrhythmias in left ventricular dysfunction. Journal of Cardiac Failure, 2004, 10, S41.	0.7	0
446	Doppler tissue imaging identifies altered activation sequences in stable heart transplant recipients. Journal of Cardiac Failure, 2004, 10, S41.	0.7	0
447	Modulation of B-Type Natriuretic Peptide with Epoprostenol in Pulmonary Arterial Hypertension. Journal of Cardiac Failure, 2004, 10, S45.	0.7	0
448	The relationship between epicardial coronary disease, tissue myocardial perfusion and survival in heart transplantation. Journal of Cardiac Failure, 2004, 10, S68.	0.7	0
449	Sildenafil and b-type natriuretic peptide modulation in chronic heart failure complicated by pulmonary hypertension. Journal of Cardiac Failure, 2004, 10, S89.	0.7	0
450	Is heart failure more prevalent in patients with peripheral arterial disease? a systematic meta-analysis. Journal of Cardiac Failure, 2004, 10, S93.	0.7	0

#	ARTICLE	IF	CITATIONS
451	Lower Hemoglobin Is Associated with Persistently Reduced Quality of Life in Unselected Patients with Heart Failure: Results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. <i>Journal of Cardiac Failure</i> , 2004, 10, S102.	0.7	0
452	Poor quality of life in chronic heart failure is independently predictive of worse short-term outcome. <i>Journal of Cardiac Failure</i> , 2004, 10, S106.	0.7	0
453	Lower hemoglobin is associated with reduced survival in unselected patients with heart failure: results from the study of anemia in a heart failure population (STAMINA-HFP) registry. <i>Journal of Cardiac Failure</i> , 2004, 10, S108.	0.7	0
454	Electronic home monitoring reduces medical resource utilization in chronic heart failure: a prospective investigation of the HomMed-sentry telemonitoring system. <i>Journal of Cardiac Failure</i> , 2004, 10, S110-S111.	0.7	4
455	Further analysis of the intravascular ultrasound data from the randomized mycophenolate mofetil (MMF) trial in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2004, 23, S42.	0.3	10
456	Metaanalysis of statins and survival in de novo cardiac transplantation. <i>Transplantation Proceedings</i> , 2004, 36, 1539-1541.	0.3	64
457	Ventricular-vascular uncoupling increases expression of B-type natriuretic peptide in heart transplantation. <i>Transplantation Proceedings</i> , 2004, 36, 3149-3151.	0.3	10
458	Corticosteroid weaning in the tacrolimus and mycophenolate era in heart transplantation: Clinical and neurohormonal benefits. <i>Transplantation Proceedings</i> , 2004, 36, 3152-3155.	0.3	21
459	White Coat Hypertension and Sleep Apnea. <i>Chest</i> , 2004, 125, 805-807.	0.4	5
460	Cardiac Troponin Levels in Heart Failure. <i>Cardiology in Review</i> , 2004, 12, 21-25.	0.6	40
461	AN UPDATE ON CLINICAL OUTCOMES IN HEART AND LUNG TRANSPLANTATION. <i>Transplantation</i> , 2004, 77, S68-S74.	0.5	14
462	Destination therapy in late-stage heart failure. <i>Coronary Artery Disease</i> , 2004, 15, 87-90.	0.3	3
463	B-type natriuretic peptide in heart transplantation: an important marker of allograft performance. <i>Heart Failure Reviews</i> , 2003, 8, 359-363.	1.7	17
464	Viscosity of Some Binary Mixtures of Arenes. <i>International Journal of Thermophysics</i> , 2003, 24, 1475-1494.	1.0	36
465	Body composition and prognosis in chronic systolic heart failure: the obesity paradox. <i>American Journal of Cardiology</i> , 2003, 91, 891-894.	0.7	447
466	Diverse Populations, New Techniques: Non-Surgical Advances in Heart Failure 2003. <i>Congestive Heart Failure</i> , 2003, 9, 189-190.	2.0	0
467	Heart failure therapy at a crossroad: are there limits to the neurohormonal model?. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1606-1610.	1.2	71
468	Beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival: Reply. <i>Journal of the American College of Cardiology</i> , 2003, 41, 2104.	1.2	1

#	ARTICLE	IF	CITATIONS
469	Clopidogrel and rhabdomyolysis after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 107-108.	0.3	9
470	Is all intimal proliferation created equal in cardiac allograft vasculopathy? The quantityâ€“quality paradox. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 118-123.	0.3	21
471	TOR inhibitors and cardiac allograft vasculopathy: is inhibition of intimal thickening an adequate surrogate of benefit?. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, 501-504.	0.3	19
472	Non-invasive molecular screening for acute cardiac rejection: a multicenter prospective clinical study. <i>Journal of Heart and Lung Transplantation</i> , 2003, 22, S74.	0.3	2
473	Title is missing!. <i>Annals of Surgery</i> , 2003, 237, 273-276.	2.1	4
474	Treatment of hypertension for patients with diastolic dysfunction. <i>Current Opinion in Cardiology</i> , 2003, 18, 272-277.	0.8	2
475	Allosensitization in heart transplantation: implications and management strategies. <i>Current Opinion in Cardiology</i> , 2003, 18, 153-158.	0.8	56
476	Gallstone Disease in Heart Transplant Recipients. <i>Annals of Surgery</i> , 2003, 237, 273-276.	2.1	29
477	Allograft transmission of hepatitis C virus infection from infected donors in cardiac transplantation. <i>Transplantation</i> , 2003, 76, 1096-1100.	0.5	25
478	The Conundrum of Sleep Breathing Disorders in Heart Failure. <i>Chest</i> , 2003, 123, 1332-1334.	0.4	4
479	Ethnic Disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. <i>Transplantation</i> , 2002, 74, 1568-1573.	0.5	53
480	Anything but a biopsy: noninvasive monitoring for cardiac allograft rejection. <i>Current Opinion in Cardiology</i> , 2002, 17, 131-136.	0.8	49
481	Renin Angiotensin Aldosterone and Adrenergic Modulation in Chronic Heart Failure: Contemporary Concepts. <i>American Journal of the Medical Sciences</i> , 2002, 324, 267-275.	0.4	10
482	Obesity, weight reduction and survival in heart failure. <i>Journal of the American College of Cardiology</i> , 2002, 39, 1563.	1.2	21
483	Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1609-1614.	1.2	106
484	Revascularization in severe ventricular dysfunction (15% â‰‰ LVEF â‰‰ 30%): a comparison of bypass grafting and percutaneous intervention. <i>Annals of Thoracic Surgery</i> , 2002, 74, 2082-2087.	0.7	47
485	Effect of immunosuppressive regimen on novel markers of atherothrombosis in heart transplantation: homocysteine, c-reactive protein, and mean platelet volume. <i>Transplantation Proceedings</i> , 2002, 34, 1866-1868.	0.3	11
486	Calcineurin-inhibitor withdrawal in heart transplantation recipients (the case against). <i>Transplantation Proceedings</i> , 2002, 34, 1825-1827.	0.3	1

#	ARTICLE	IF	CITATIONS
487	Steroid weaning in heart transplantation is associated with decreased b-type natriuretic peptide.: Transplantation Proceedings, 2002, 34, 1843-1844.	0.3	5
488	Bedside b-type natriuretic peptide and acute non-cellular cardiac allograft rejection. Journal of Heart and Lung Transplantation, 2002, 21, 613-614.	0.3	17
489	Usefulness of the combined index of systolic and diastolic myocardial performance to identify cardiac allograft rejection. American Journal of Cardiology, 2002, 90, 517-520.	0.7	47
490	Crumbling of left ventricular hypertrophy as a surrogate end point (the Losartan for Intervention) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 1133-1134.	0.7	9
491	Usefulness of B-type natriuretic peptide levels in predicting hemodynamic perturbations after heart transplantation despite preserved left ventricular systolic function. American Journal of Cardiology, 2002, 90, 1326-1329.	0.7	55
492	Emergence of Laplace Therapeutics: Declaring an End to "End-stage" Heart Failure. Congestive Heart Failure, 2002, 8, 228-234.	2.0	6
493	Treatment of pulmonary hypertension: A promising new age. Catheterization and Cardiovascular Interventions, 2002, 57, 395-403.	0.7	1
494	Is heart failure with preserved systolic function an overlooked enigma?. Current Cardiology Reports, 2002, 4, 187-193.	1.3	5
495	Treatment of heart failure according to William Stokes: The enchanted mercury. Journal of Cardiac Failure, 2001, 7, 277-282.	0.7	8
496	Desperate diseases, desperate measures: Tackling malignant hypertension in the 1950s. American Heart Journal, 2001, 142, 197-203.	1.2	15
497	Are there specific risk factors for fatal allograft vasculopathy? An analysis of over 7,000 cardiac transplant patients. Journal of Heart and Lung Transplantation, 2001, 20, 152.	0.3	17
498	Reversibility of anorexigenic valvulopathy: Reply. Annals of Thoracic Surgery, 2001, 71, 397.	0.7	0
499	Ethnic disparities in the pharmacologic characteristics of tacrolimus in heart transplantation. Transplantation Proceedings, 2001, 33, 1581-1582.	0.3	11
500	A randomized comparison of an immunosuppressive strategy using tacrolimus and cyclosporine in black heart transplant recipients. Transplantation Proceedings, 2001, 33, 1606-1607.	0.3	11
501	Racial differences in clinical outcome using tacrolimus and mycophenolate mofetil immunosuppression in heart transplantation. Transplantation Proceedings, 2001, 33, 1613-1614.	0.3	8
502	THE DILEMMA OF LATE-STAGE HEART FAILURE. Cardiology Clinics, 2001, 19, 627-636.	0.9	6
503	SAFETY, TOLERABILITY, AND EFFICACY OF CYCLOSPORINE MICROEMULSION IN HEART TRANSPLANT RECIPIENTS: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND COMPARISON WITH THE OIL-BASED FORMULATION OF CYCLOSPORINE???RESULTS AT 24 MONTHS AFTER TRANSPLANTATION1. Transplantation, 2001, 71, 70-78.	0.5	39
504	Update on left ventricular assist devices as a bridge to recovery. Current Opinion in Organ Transplantation, 2001, 6, 211-215.	0.8	5



#	ARTICLE	IF	CITATIONS
505	Laparoscopic and Thoracoscopic Esophagomyotomy for Children With Achalasia. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2001, 33, 466-471.	0.9	38
506	Insights into ventricular repolarization abnormalities in cardiac allograft vasculopathy. <i>American Journal of Cardiology</i> , 2001, 87, 367-368.	0.7	15
507	Novel Diagnostic Markers in Heart Failure: An Emerging Paradigm Shift?. <i>Congestive Heart Failure</i> , 2001, 7, 274-276.	2.0	2
508	Emergence of Electronic Home Monitoring in Chronic Heart Failure: Rationale, Feasibility, and Early Results With the HomMed Sentry?-Observer? System. <i>Congestive Heart Failure</i> , 2000, 6, 137-139.	2.0	16
509	Bridging Patients to Cardiac Transplantation. <i>Congestive Heart Failure</i> , 2000, 6, 238-243.	2.0	14
510	Robert James Graves and the cardiovascular responses to postural changes in heart failure. <i>American Journal of Cardiology</i> , 2000, 85, 1503-1506.	0.7	5
511	Study of Arterial and Autonomic Effects of Cyclosporine in Humans. <i>Hypertension</i> , 2000, 35, 1258-1263.	1.3	30
512	Crossing the vasculopathy bridge from morphology to therapy: a single center experience. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 522-528.	0.3	20
513	Long-term outcome of cardiac allograft vasculopathy treated by transmyocardial laser revascularization: early rewards, late losses. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 801-804.	0.3	14
514	The incremental prognostic importance of body fat adjusted peak oxygen consumption in chronic heart failure. <i>Journal of the American College of Cardiology</i> , 2000, 36, 2126-2131.	1.2	175
515	Cardiac allograft valvulopathy: a case of donor-anorexigen-induced valvular disease. <i>Annals of Thoracic Surgery</i> , 1999, 68, 1840-1841.	0.7	7
516	Intravenous thyroid hormone supplementation in heart failure with cardiogenic shock. <i>Journal of Cardiac Failure</i> , 1999, 5, 31-37.	0.7	43
517	Effects of Aerobic Exercise Training on Indices of Ventricular Repolarization in Patients With Chronic Heart Failure. <i>Chest</i> , 1999, 116, 83-87.	0.4	52
518	LONG-TERM OUTCOME OF TRANSMYOCARDIAL LASER REVASCULARIZATION IN CARDIAC ALLOGRAFT VASCULOPATHY: EARLY REWARDS, LATE LOSSES. <i>Transplantation</i> , 1999, 67, S38.	0.5	1
519	PREDICTING SURVIVAL IN URGENT (STATUS I) HEART TRANSPLANTATION: A CLINICAL PROGNOSTIC MODEL. <i>Transplantation</i> , 1999, 67, S253.	0.5	0
520	THE IMMUNOMODULATORY IMPACT OF THEOPHYLLINE ON CARDIAC ALLOGRAFT REJECTION. <i>Transplantation</i> , 1999, 67, S26.	0.5	0
521	THE QUANTITATIVE IMPACT OF FLOW CYTOMETRIC CROSSMATCH ON INDICES OF CARDIAC ALLOGRAFT REJECTION. <i>Transplantation</i> , 1999, 67, S267.	0.5	0
522	Three-Year Allograft Vasculopathy Results of the Multicenter Heart Transplant Mycophenolate Mofetil Randomized Trial. <i>Transplantation</i> , 1999, 67, S543.	0.5	1

#	ARTICLE	IF	CITATIONS
523	Colles-Stokes Contributions to the Concept of Heart Failure. American Journal of Cardiology, 1998, 81, 1470-1473.	0.7	9
524	Effects of caregiver specialty on cost and clinical outcomes following hospitalization for heart failure. American Journal of Cardiology, 1998, 82, 82-85.	0.7	119
525	Modulatory impact of cardiac rehabilitation on hyperhomocysteinemia in patients with coronary artery disease and "normal" lipid levels. American Journal of Cardiology, 1998, 82, 1543-1545.	0.7	39
526	Coronary stenting in cardiac allograft vasculopathy. Journal of the American College of Cardiology, 1998, 32, 1636-1640.	1.2	44
527	Mucin Secretion in Inflammatory Bowel Disease: Comparison of a Macrophage-Derived Mucin Secretagogue (MMS-68) to Conventional Secretagogues. Inflammatory Bowel Diseases, 1998, 4, 12-17.	0.9	7
528	Population Based Impact of a Heart Failure Care Model Designed to Reduce Medical Resource Utilization in a Managed Care Environment. Journal of the American College of Cardiology, 1998, 31, 306A.	1.2	1
529	Home Inotropic Therapy in Advanced Heart Failure. Chest, 1997, 112, 1298-1303.	0.4	50
530	Heterosexual behaviour and condom usage in an urban population of Delhi, India. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 1997, 9, 311-318.	0.6	18
531	CYCLOSPORINE-INDUCED HYPERTENSION IN CARDIAC TRANSPLANTATION. Medical Clinics of North America, 1997, 81, 1347-1357.	1.1	26
532	Implications for the vascular surgeon with prolonged (3 to 89 days) intraaortic balloon pump counterpulsation. Journal of Vascular Surgery, 1997, 26, 511-516.	0.6	27
533	Renin-angiotensin system: Genes to bedside. American Heart Journal, 1997, 134, 514-526.	1.2	56
534	Allograft aortopathy: An in vivo study of donor aorta involvement in cardiac allograft vasculopathy. American Heart Journal, 1997, 133, 698-702.	1.2	14
535	Heterogeneity of Cardiac Allograft Vasculopathy: Clinical Insights From Coronary Angioscopy. Journal of the American College of Cardiology, 1997, 29, 1339-1344.	1.2	31
536	The unique management of refractory advanced systolic heart failure. Heart and Lung: Journal of Acute and Critical Care, 1997, 26, 280-288.	0.8	1
537	Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Current Opinion in Cardiology, 1997, 12, 375-381.	0.8	72
538	Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. American Journal of Cardiology, 1997, 80, 61-64.	0.7	82
539	Management of Cardiac Allograft Vasculopathy by Transmyocardial Laser Revascularization. American Journal of Cardiology, 1997, 80, 224-225.	0.7	15
540	Lipid-Lowering Therapy and Long-Term Survival in Heart Transplantation. American Journal of Cardiology, 1997, 80, 802-805.	0.7	24

#	ARTICLE	IF	CITATIONS
541	Usefulness of Peak Oxygen Consumption in Predicting Outcome of Heart Failure in Women Versus Men. <i>American Journal of Cardiology</i> , 1997, 80, 1236-1238.	0.7	37
542	The Incidence, Morbidity, and Mortality of Surgical Procedures After Orthotopic Heart Transplantation. <i>Annals of Surgery</i> , 1997, 225, 686-694.	2.1	39
543	Cyclosporine induced hypertension: Evidence for maintained baroreflex circulatory control. <i>Journal of the American College of Cardiology</i> , 1996, 27, 219.	1.2	2
544	Predicting Prognosis in Advanced Heart Failure. <i>Chest</i> , 1996, 110, 310-312.	0.4	18
545	On-Line Myocardial Tissue Characterization with a New Commercially Produced Software. <i>Echocardiography</i> , 1996, 13, 271-279.	0.3	2
546	The Clinical Relevance of Circulating Tumor Necrosis Factor- $\alpha$ in Acute Decompensated Chronic Heart Failure Without Cachexia. <i>Chest</i> , 1996, 110, 992-995.	0.4	71
547	An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. <i>American Journal of Cardiology</i> , 1995, 75, 853-854.	0.7	102
548	Cardiac allograft vasculopathy: Current concepts. <i>American Heart Journal</i> , 1995, 129, 791-799.	1.2	112
549	Predictive model to assess risk for cardiac allograft vasculopathy: An intravascular ultrasound study. <i>Journal of the American College of Cardiology</i> , 1995, 26, 1537-1544.	1.2	84
550	Review: ACE inhibitors reduce mortality and hospitalization in congestive heart failure. <i>ACP Journal Club</i> , 1995, 123, 62.	0.1	2
551	Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. <i>American Journal of Cardiology</i> , 1994, 74, 1042-1046.	0.7	87
552	Fluvastatin in primary hypercholesterolemia: Efficacy and safety in patients at high risk. <i>American Journal of Medicine</i> , 1994, 96, S79-S83.	0.6	14
553	Long-term treatment of hypercholesterolemia with fluvastatin: A 52-week multicenter safety and efficacy study. <i>American Journal of Medicine</i> , 1994, 96, S87-S93.	0.6	20
554	Efficacy of a low dose range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose response study in 431 patients. The French-Dutch Fluvastatin Study Group. <i>British Journal of Clinical Pharmacology</i> , 1994, 38, 257-263.	1.1	24
555	Efficacy and Safety of Fluvastatin in Women with Primary Hypercholesterolaemia. <i>Drugs</i> , 1994, 47, 64-72.	4.9	11
556	Efficacy and Safety of Fluvastatin in Hypertensive Patients: An Analysis of a Clinical Trial Database. <i>American Journal of Hypertension</i> , 1993, 6, 340S-345S.	1.0	20
557	Safety and Tolerability of Fluvastatin With Concomitant Use of Antihypertensive Agents: An Analysis of a Clinical Trial Database. <i>American Journal of Hypertension</i> , 1993, 6, 346S-352S.	1.0	12
558	Abdominal Pain in a Patient Who Had Had Cancer. <i>Hospital Practice (1995)</i> , 1992, 27, 221-222.	0.5	0

#	ARTICLE	IF	CITATIONS
559	Device Degradation on a Full-Frame CCD Image Sensor with a Transparent Gate Electrode. Materials Research Society Symposia Proceedings, 1992, 262, 803.	0.1	1
560	Radiocontrast-induced nephropathy. Postgraduate Medicine, 1992, 92, 215-223.	0.9	3
561	Ventricular standstill complicating left heart catheterization in the presence of uncomplicated right bundle branch block. Catheterization and Cardiovascular Diagnosis, 1992, 27, 212-214.	0.7	9
562	Contralateral femoral neuropathy: An unusual complication of anticoagulation following PTCA. Catheterization and Cardiovascular Diagnosis, 1991, 24, 176-178.	0.7	4
563	Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion.. Journal of Cell Biology, 1990, 110, 529-540.	2.3	368
564	Electrical resistivity and structural changes upon relaxation and crystallisation of (Mo <sub>0.6</sub> Ru <sub>0.4</sub> ) <sub>100-x</sub> B <sub>x</sub> metallic glasses. Journal of Physics F: Metal Physics, 1985, 15, 2109-2120.	1.6	6
565	The structure and properties of some Rh <sub>0.92-x</sub> B <sub>x</sub> Si <sub>0.08</sub> metallic glasses. Journal of Physics F: Metal Physics, 1982, 12, 1861-1868.	1.6	1
566	Distribution of mercury in subcellular fractions of brain, liver, and kidney after repeated oral administration of <sup>203</sup> Hg-labeled methylmercuric chloride in mice. Experimental and Molecular Pathology, 1981, 35, 435-447.	0.9	13
567	Distribution and Biotransformation of Methyl Mercuric Chloride in Different Tissues of Mice. Acta Pharmacologica Et Toxicologica, 1981, 49, 28-37.	0.0	21
568	Absorption, distribution, and excretion of methylmercury in mice. Bulletin of Environmental Contamination and Toxicology, 1980, 24, 627-633.	1.3	22
569	Anomalous behavior of amorphous Fe-B alloys. IEEE Transactions on Magnetics, 1980, 16, 1141-1143.	1.2	4
570	Biochemical changes resulting from the intraperitoneal administration of mercuric chloride and methylmercuric chloride to mice. Toxicology Letters, 1980, 6, 319-326.	0.4	23
571	Absorption, distribution and excretion of Hg <sup>203</sup> in mice. Bulletin of Environmental Contamination and Toxicology, 1979, 21, 733-736.	1.3	6
572	Multiple-factor rules for sequencing with assembly constraints. Naval Research Logistics Quarterly, 1968, 15, 241-254.	0.4	56
573	Postoperative care and early complications. , 0, , 94-101.		0